A Phase 2 interventional study of NNC0365-3769 (Mim8) and Placebo (Mim8) in Healthy Volunteers and Haemophilia A With or Without Inhibitors, sponsored by Novo Nordisk A/S. Completed at 40 sites in 12 countries. Open to male participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-19.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 3rd largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2020, is one of 7 in phase 2, and was the 69th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States, Argentina, Australia and 15 more countries
Ages 18+
Novo Nordisk A/S · Sites in United States, Austria, Belgium and 9 more countries
Ages 18–64 · Men only · Healthy volunteers
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 12+
Novo Nordisk A/S · Sites in India, Malaysia, Korea, Republic of and 1 more country
By country, each count listing its studies:
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: 12 Years and older · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 3 started in 2020.
This study's enrollment of 275 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 38 across the 59 interventional studies, 86 across the 32 observational. Of the 78 that completed or were terminated, 20 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
4 of the studies in Hemophilia A by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04682145Novo Nordisk A/SAdverse Event Data Collection From the EUHASS Registry on Turoctocog Alfa Pegol | 2026-12-01 |
| NCT07653139Novo Nordisk A/SPatient Preferences in Treatment of Haemophilia A With and Without Inhibitors: a Discrete Choice Experiment in Germany | 2026-12-26 |
| NCT07220564Novo Nordisk A/SA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A | 2027-02-05 |
| NCT04574076Novo Nordisk A/SA Study Following Males With Haemophilia A on Prophylaxis With Esperoct® | 2027-06-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 92 studies in Hemophilia A by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is investigating how Mim8 works in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medication that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected with a thin needle in the skin of the stomach, using a pen-injector.
The study will last for up to 44 months. It consists of a main phase (part 1 and part 2) and an extension phase. In part 1, participants will be injected only once with either Mim8 or a "dummy" medicine (placebo) - which one will be decided by chance. In part 2 and the extension phase participants will get an Mim8 injection weekly or monthly.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Single ascending dose part 1:
Multiple ascending dose part 2:
Exploratory biomarker cohort:
Exclusion Criteria:
Part 1:
Part 2:
Exploratory biomarker cohort:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blinded. Single doses in healthy volunteers. Dose escalation. In each of the 6 cohorts, 6 participants will receive Mim8.
Drug: NNC0365-3769 (Mim8)
Blinded. Single doses in healthy volunteers. In each of the 6 cohorts, 2 participants will receive placebo.
Drug: Placebo (Mim8)
Open-label. There will be 4 cohorts receiving once-weekly doses (part 2 cohorts 1, 2, 3 and 5) and one cohort receiving once-monthly doses (part 2 cohort 4). Participants will continue into the part 2 extension on the same treatment regimen.
Drug: NNC0365-3769 (Mim8)
Mim8 administered subcutaneously (s.c., under the skin). The treatment period will consist of 12 once-weekly doses or 3 once-monthly doses
Mim8 placebo administered subcutaneously (s.c., under the skin)
Part 1: Number of treatment emergent adverse events
Count
Time frame: From time of dosing (Day 1) to Week 16
Part 2: Number of treatment emergent adverse events
Count
Time frame: From time of first dosing (Day 1) to Week 12
Part 2, extension: Number of treatment emergent adverse events
Count
Time frame: From Week 12 up to Week 176 (16 weeks after last dose)
Part 1: Number of injection site reactions
Count
Time frame: From time of dosing (Day 1) to Week 16
Part 1: Relative change in D-dimer
Percent
Time frame: From baseline (Day 1) to Week 16
Part 1: Relative change in prothrombin fragment 1 and 2
Percent
Time frame: From baseline (Day 1) to Week 16
Part 1: Relative change in fibrinogen
Percent
Time frame: From baseline (Day 1) to Week 16
Part 1: Relative change in platelets
Percent
Time frame: From baseline (Day 1) to Week 16
Part 1: Cmax, SD: the maximum concentration of Mim8 after a single dose
μg/mL
Time frame: From baseline (Day 1) to Week 16
Part 1: AUC0-inf, SD: the area under the Mim8 concentration-time curve from time 0 to infinity after a single dose
μg\*day/mL
Time frame: From baseline (Day 1) to Week 16
Part 1: t1/2, SD: the terminal half-life of Mim8 after a single dose
Days
Time frame: From baseline (Day 1) to Week 16
Part 1: tmax, SD: the time to maximum concentration of Mim8 after a single dose
Days
Time frame: From baseline (Day 1) to Week 16
Part 1: Change in activated partial thromboplastin time
Seconds
Time frame: From baseline (Day 1) to Week 16
Part 2 (weekly and monthly dosing): Number of injection site reactions
Count
Time frame: From time of first dosing (Day 1) to Week 12
Part 2 (weekly and monthly dosing): Occurrence of anti-Mim8 antibodies
Count
Time frame: From baseline (Day 1) to Week 12
Part 2 (weekly and monthly dosing): Relative change in D-dimer
Percent
Time frame: From baseline (Day 1) to Week 12
Part 2 (weekly and monthly dosing): Relative change in prothrombin fragment 1 and 2
Percent
Time frame: From baseline (Day 1) to Week 12
Part 2 (weekly and monthly dosing): Relative change in fibrinogen
Percent
Time frame: From baseline (Day 1) to Week 12
Part 2 (weekly and monthly dosing): Relative change in platelets
Percent
Time frame: From baseline (Day 1) to Week 12
Part 2 PK session 2 (weekly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses
μg/mL
Time frame: From Day 57 to Day 64
Part 2 PK session 2 (weekly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses
μg\*day/mL
Time frame: From Day 57 to Day 64
Part 2 PK session 2 (monthly dosing): Cmax, MD: the maximum concentration of Mim8 after multiple doses
μg/mL
Time frame: From Day 57 to Day 85
Part 2 PK session 2 (monthly dosing): AUCτ, MD: the area under the Mim8 concentration-time curve in the dosing interval after multiple doses
μg\*day/mL
Time frame: From Day 57 to Day 85
Part 2 (weekly dosing): Mean of maximum thrombin generation (peak height)
nM
Time frame: From Day 57 to Day 64
Part 2 (monthly dosing): Mean of maximum thrombin generation (peak height)
nM
Time frame: From Day 57 to Day 85
Part 2, extension: Number of injection site reactions
Count
Time frame: From Week 12 up to Week 176 (16 weeks after last dose)
Part 2, extension: Occurrence of anti-Mim8 antibodies
Count
Time frame: From Week 12 up to Week 176 (16 weeks after last dose)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Jan 2020 to primary completion in Oct 2023, 44 months.
Of 18 phase 2 interventional studies under Hemophilia A, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 20. This study's 44 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denecimig